EXELIXIS
Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, ... although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.
EXELIXIS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1994-01-01
Address:
Alameda, California, United States
Country:
United States
Website Url:
http://www.exelixis.com
Total Employee:
251+
Status:
Active
Contact:
+1 6508378300
Total Funding:
379 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Font Awesome Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2004-10-19 | X-Ceptor Therapeutics, Inc. | X-Ceptor Therapeutics, Inc. acquired by Exelixis | N/A |
| 2001-11-20 | Genomica S.A.U. | Genomica S.A.U. acquired by Exelixis | 110 M USD |
| 2001-04-23 | TaconicArtemis GmbH | TaconicArtemis GmbH acquired by Exelixis | N/A |
| 2000-09-08 | Agritope | Agritope acquired by Exelixis | 68 M USD |
| 1999-07-12 | Metaxen LLC | Metaxen LLC acquired by Exelixis | N/A |
Investors List
Deerfield
Deerfield investment in Post-IPO Debt - Exelixis
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Exelixis
Deerfield
Deerfield investment in Post-IPO Debt - Exelixis
PaineWebber
PaineWebber investment in Seed Round - Exelixis
Atlas Venture
Atlas Venture investment in Seed Round - Exelixis
Oxford Bioscience Partners
Oxford Bioscience Partners investment in Seed Round - Exelixis
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-04 | Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer |
Official Site Inspections
http://www.exelixis.com Semrush global rank: 754.17 K Semrush visits lastest month: 53.31 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
